Company Overview of Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. develops compounds for the treatment of acromegaly and certain hormone active tumor types resulting from hypophyse disorders. It offers Somatoprim (DG3173), a novel somatostatin analogue that regulates endocrine system and affects neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin receptors and inhibition of the release of various secondary hormones. The company provides Somatoprim to treat patients with the various indications, including acromegaly, carcinoid tumors, GEP-NET, diabetic retinopathy, and cushings diseases. Aspireo Pharmaceuticals Ltd. is based in Tel Aviv, Israel.
Key Executives for Aspireo Pharmaceuticals Ltd.
Similar Private Companies By Industry
|Accelerated Evolution Biotechnologies Ltd||Middle East/Africa|
|Adante Ltd.||Middle East/Africa|
|Advanced Biotechnology Ltd.||Middle East/Africa|
|Advanced Medical Analysis (AMA) Ltd.||Middle East/Africa|
|Advanced Neuroprotective System Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Aspireo Pharmaceuticals Ltd., please visit www.aspireopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.